ATE483712T1 - Hcv-ns5b-inhibitoren - Google Patents

Hcv-ns5b-inhibitoren

Info

Publication number
ATE483712T1
ATE483712T1 AT07763294T AT07763294T ATE483712T1 AT E483712 T1 ATE483712 T1 AT E483712T1 AT 07763294 T AT07763294 T AT 07763294T AT 07763294 T AT07763294 T AT 07763294T AT E483712 T1 ATE483712 T1 AT E483712T1
Authority
AT
Austria
Prior art keywords
hcv ns5b
ns5b inhibitors
compounds
hcv
inhibitors
Prior art date
Application number
AT07763294T
Other languages
German (de)
English (en)
Inventor
Carl Bergstrom
Scott Martin
Thomas Hudyma
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE483712T1 publication Critical patent/ATE483712T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
AT07763294T 2006-02-08 2007-02-07 Hcv-ns5b-inhibitoren ATE483712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77139106P 2006-02-08 2006-02-08
PCT/US2007/061768 WO2007092888A2 (en) 2006-02-08 2007-02-07 Hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
ATE483712T1 true ATE483712T1 (de) 2010-10-15

Family

ID=38234480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07763294T ATE483712T1 (de) 2006-02-08 2007-02-07 Hcv-ns5b-inhibitoren

Country Status (17)

Country Link
US (1) US7456165B2 (enExample)
EP (1) EP1987038B1 (enExample)
JP (1) JP5147731B2 (enExample)
KR (1) KR20080102161A (enExample)
CN (1) CN101379066B (enExample)
AT (1) ATE483712T1 (enExample)
AU (1) AU2007211988B2 (enExample)
CY (1) CY1111423T1 (enExample)
DE (1) DE602007009646D1 (enExample)
DK (1) DK1987038T3 (enExample)
ES (1) ES2352574T3 (enExample)
HR (1) HRP20100672T1 (enExample)
NO (1) NO20083513L (enExample)
PL (1) PL1987038T3 (enExample)
PT (1) PT1987038E (enExample)
SI (1) SI1987038T1 (enExample)
WO (1) WO2007092888A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
JP5205370B2 (ja) * 2006-05-25 2013-06-05 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
JP2011517673A (ja) 2008-03-27 2011-06-16 ブリストル−マイヤーズ スクイブ カンパニー 芳香族ヘテロ環縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
AU2009228337A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2416062T3 (es) * 2008-03-27 2013-07-30 Bristol-Myers Squibb Company Inhibidores de NS5B del VHC de indolobenzadiazepina condensados con pirrolidina
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
WO2010093359A1 (en) * 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102276531A (zh) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 一种甲磺酸非诺多泮的制备方法
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104447952A (zh) * 2014-12-11 2015-03-25 上海唐润医药科技有限公司 丙肝病毒蛋白酶抑制剂及其合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
CA2521678A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
DE502005002697D1 (de) 2004-10-13 2008-03-13 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
US7662809B2 (en) 2004-10-26 2010-02-16 Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors

Also Published As

Publication number Publication date
CY1111423T1 (el) 2015-08-05
CN101379066A (zh) 2009-03-04
CN101379066B (zh) 2011-08-03
EP1987038B1 (en) 2010-10-06
WO2007092888A3 (en) 2007-10-11
EP1987038A2 (en) 2008-11-05
AU2007211988B2 (en) 2012-02-02
KR20080102161A (ko) 2008-11-24
PL1987038T3 (pl) 2011-03-31
US20070185083A1 (en) 2007-08-09
DE602007009646D1 (de) 2010-11-18
PT1987038E (pt) 2010-12-09
WO2007092888A2 (en) 2007-08-16
DK1987038T3 (da) 2011-01-31
AU2007211988A1 (en) 2007-08-16
JP5147731B2 (ja) 2013-02-20
NO20083513L (no) 2008-10-14
JP2009526081A (ja) 2009-07-16
ES2352574T3 (es) 2011-02-21
HRP20100672T1 (hr) 2011-01-31
US7456165B2 (en) 2008-11-25
SI1987038T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
DK1987038T3 (da) HCV NS5B-hæmmere
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
EA200900697A1 (ru) Ингибиторы вируса гепатита с
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
EA200900676A1 (ru) Ингибиторы вируса гепатита с
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
EA200900298A1 (ru) Ингибиторы вируса гепатита с
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.
UA95990C2 (en) Hcv ns3 protease inhibitors
ATE531373T1 (de) Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1987038

Country of ref document: EP